DTA

• UNSPSC Description:

  DTA (2,4-Disulfamyl-5-trifluoromethylaniline) is a cyclic AMP phosphodiesterase inhibitor that binds to erythrocyte carbonic anhydrase[1][2].

• Target Antigen:

  Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Others

• Assay Protocol:

  https://www.medchemexpress.com/dta.html

• Solubility:

  10 mM in DMSO

• Smiles:

  FC(F)(F)C1=CC(N)=C(S(N)(=O)=O)C=C1S(N)(=O)=O

• Molecular Weight:

  319.28

• References & Citations:

  [1]Brørs O, et al. Pharmacokinetics of hydroflumethiazide during repeated oral administration to healthy subjects. Eur J Clin Pharmacol. 1979 May 21;15(4):281-6. |[2]Brørs O, et al. Interaction of hydroflumethiazide and 2,4-disulfamyl-5-trifluoromethylaniline with cyclic AMP phosphodiesterase and carbonic anhydrase. Acta Pharmacol Toxicol (Copenh). 1982 Oct;51(4):273-7.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 2

• CAS Number:

  654-62-6